The 35 rating InvestorsObserver gives to Nektar Therapeutics (NKTR) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 17 percent of stocks in the Biotechnology industry, NKTRs 35 overall rating means the stock scores better than 35 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Nektar Therapeutics (NKTR) stock is down -4.22% while the S&P 500 is unchanged 0% as of 10:21 AM on Friday, May 1. NKTR is down -$0.81 from the previous closing price of $19.20 on volume of 112,808 shares. Over the past year the S&P 500 is lower by -0.17% while NKTR is down -42.78%. NKTR lost -$2.52 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the original post here:
Is Nektar Therapeutics (NKTR) a Winner or a Loser in the Biotechnology Industry? - InvestorsObserver

Research report on global Biotechnology Reagents Market 2020 with industry-primary research, secondary research, product research, size, trends, and Forecast.

The Biotechnology Reagents report provides independent information about the Biotechnology Reagents industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Biotechnology Reagents Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Biotechnology Reagents Market: Products in the Biotechnology Reagents classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Life Technologies, (U.S.), Bio-Rad (U.S.), Thermo Fisher Scientific (U.S.), Water Corporation (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies Inc. (U.S.), Betcon Dickinson (U.S.), Beckman Coulter (U.S.), Roche (Switzerland), Abbott (U.S.)

Table Of Content

Market Overview: Scope & Product Overview, Classification of Biotechnology Reagents by Product Category (Market Size (Sales), Market Share Comparison by Type (Product Category)), Biotechnology Reagents Market by Application/End Users (Sales (Volume) and Market Share Comparison by Application), Market by Region (Market Size (Value) Comparison by Region, Status and Prospect

Biotechnology Reagents Market by Manufacturing Cost Analysis: Key Raw Materials Analysis, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials, Proportion of Manufacturing Cost Structure (Raw Materials, Labor Cost), Manufacturing Process Analysis

Biotechnology Reagents Market Report Covers the Following Segments:

Segment by Type:

Life scienceAnalytical

Segment by Application:

Protein synthesis and purificationGene expressionDNA and RNA analysisDrug testing

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Key Benefits for Stakeholders

The study provides an in-depth analysis of the Biotechnology Reagents market size along with the current trends and future estimations to elucidate the imminent investment pockets.

Information about key drivers, restraints, and opportunities and their impact analysis on the market size is provided.

Porters five forces analysis illustrates the potency of buyers and suppliers operating in the portable gaming industry.

The quantitative analysis of the Biotechnology Reagents industry from 2020 to 2026 is provided to determine the Biotechnology Reagents market potential.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follow this link:
Biotechnology Reagents Market is poised to achieve continuing growth During Forecast Period 2020-2026 - Cole of Duty

The company will use ranpirnase to target human papillomavirus (HPV), which causes genital warts

Inc (),a global biotechnology company, has completed the acquisition of Tamir Biotechnology Inc and its broad spectrum antiviral platform, ranpirnase.

The deal included cash and stock of roughly $21 million.

The company will use ranpirnase to target human papillomavirus (HPV), which causes genital warts. A topical version of ranpirnase was evaluated in Phase 1/2 clinical trials targeting genital warts, and it demonstrated a clear clinical effect and a good safety profile, the group noted..

READ: Orgenesis to acquire assets of Tamir Biotechnology and its anti-viral platform ranpirnase for $19M

Going forward, Orgenesis said it plans to move the program through a Phase 2b trial in the US. Additionally, the company will undergo a new clinical trial targeting anal dysplasia, a precusor to anal cancer driven by the HPV virus.

"We are pleased to have closed this transaction, as we believe that ranpirnase holds promise as a broad antiviral platform, CEO Vered Caplan said in a statement.

Ranpirnase has demonstrated clinical efficacy against HPV and other hard to target viruses based on its unique mechanism of action, killing the virus and modulating the immune system, as evidenced by preclinical activity against some of the world's most persistent viral threats. For this reason, we are aggressively pursuing a number of complementary approaches internally to maximize the potential of ranpirnase," he added.

Ranpirnase is a member of the superfamily of enzymes that cause the degradation of RNA and mediate biological activities, including cell death.

Germantown, Maryland-based Orgenesis is a vertically-integrated biopharmaceutical company with expertise in developing advanced cell therapies and manufacturing.

Contact Andrew Kessel at [emailprotected]

Follow him on Twitter @andrew_kessel

See original here:
Orgenesis closes acquisition of Tamir Biotechnology and its antiviral platform ranpiranse - Proactive Investors USA & Canada

Two prominent biotechnology scientists from The University of Manchester have been confirmed as Royal Society Fellows among more than 60 of their peers across the world.

Professor Nigel Scrutton and Professor Nicholas Turner from the Manchester Institute of Biotechnology have been awarded the prestigious Fellowships thanks to their pioneering contributions to scientific discovery in the field of industrial biotechnology one of the key research beacons for The University of Manchester.

The 51 new Fellows, 10 Foreign Members and one Honorary Fellow have been selected for their outstanding contributions to scientific understanding. With discoveries ranging from the first planets outside our solar system, to the creation of the worlds smallest molecular engine, new mathematical proofs and treatments for debilitating global disease.

The new Fellows embody the global nature of science, with representation from Sweden, Israel, Germany, Australia, Canada, UK-born scientists working in Europe and beyond, and researchers from around the world enriching Britains own research and innovation sector. Their ranks include six Nobel laureates, as well as internationally recognised leaders in industry and science policy.

Venki Ramakrishnan, President of the Royal Society, said: At this time of global crisis, the importance of scientific thinking, and the medicines, technologies and insights it delivers, has never been clearer. Our Fellows and Foreign Members are central to the mission of the Royal Society, to use science for the benefit of humanity.

While election to the Fellowship is a recognition of exceptional individual contributions to the sciences, it is also a network of expertise that can be drawn on to address issues of societal, and global significance. This years Fellows and Foreign Members have helped shape the 21st century through their work at the cutting-edge of fields from human genomics, to climate science and machine learning.

It gives me great pleasure to celebrate these achievements, and those yet to come, and welcome them into the ranks of the Royal Society.

See the original post:
Outstanding MIB scientists elected as Fellows of the Royal Society - The University of Manchester

Volatility in Focus:

The stock unfolded volatility at 6.97% during a week and it has been swapped around 11.65% over a month. Volatility is a rate at which the price of a security increases or decreases for a given set of returns. Volatility is measured by calculating the standard deviation of the annualized returns over a given period of time. It shows the range to which the price of a security may increase or decrease. Volatility measures the risk of a security. It is used in option pricing formula to gauge the fluctuations in the returns of the underlying assets. Volatility indicates the pricing behavior of the security and helps estimate the fluctuations that may happen in a short period of time. If the prices of a security fluctuate rapidly in a short time span, it is termed to have high volatility. If the prices of a security fluctuate slowly in a longer time span, it is termed to have low volatility.

The average true range is a volatility indicator. This stocks Average True Range (ATR) is currently standing at 4.39.

Vir Biotechnology (VIR) stock Trading Summary:

Vir Biotechnology (VIR) stock changed position at -1.54% to closing price of $30.08 in recent trading session. The last closing price represents the price at which the last trade occurred. The last price is also the price on which most charts are based; the chart updates with each change of the last price. The stock registered Wednesday volume of 944495 shares. Daily volume is the number of shares that are traded during one trading day. High volume is an indication that a stock is actively traded, and low volume is an indication that a stock is less actively traded. Some stocks tend always to have high volume, as they are popular among day traders and investors alike. Other stocks tend always to have low volume, and arent of particular interest to short-term traders. The stock average trading capacity stands with 1.11M shares and relative volume is now at 0.85.

Vir Biotechnology (VIR):

If you are considering getting into the day trading or penny stock market, its a legitimate and profitable method for making a living. Every good investor knows that in order to make money on any investment, you must first understand all aspects of it, so lets look at daily change, stock price movement in some particular time frame, volatility update, performance indicators and technical analysis and analyst rating. Picking a stock is very difficult job. There are many factors to consider before choosing a right stock to invest in it. If picking stock was easy, everyone would be rich right? This piece of financial article provides a short snap of Vir Biotechnology (VIR) regarding latest trading session and presents some other indicators that can help you to support yours research about Vir Biotechnology (VIR).

Vir Biotechnology (VIR) Stock Price Movement in past 50 Days period and 52-Week period

Vir Biotechnology (VIR) stock demonstrated 158.19% move opposition to 12-month low and unveiled a move of -59.89% versus to 12-month high. The recent trading activity has given its price a change of -59.89% to its 50 Day High and 86.95% move versus to its 50 Day Low. Prices of commodities, securities and stocks fluctuate frequently, recording highest and lowest figures at different points of time in the market. A figure recorded as the highest/lowest price of the security, bond or stock over the period of past 52 weeks is generally referred to as its 52-week high/ low. It is an important parameter for investors (as they compare the current trading price of the stocks and bonds to the highest/lowest prices they have reached in the past 52 weeks) in making investment decisions. It also plays an important role in determination of the predicted future prices of the stock.

Vir Biotechnology (VIR) Stock Past Performance

Vir Biotechnology (VIR) stock revealed -17.84% return for the recent month and disclosed 81.86% return in 3-month period. The stock grabbed 108.74% return over last 6-months. To measure stock performance since start of the year, it resulted a change of 139.20%. Past performance shows you the funds track record, but do remember that past performance is not an indication of future performance. Read the historical performance of the stock critically and make sure to take into account both long- and short-term performance. Past performance is just one piece of the puzzle when evaluating investments. Understanding how performance fits in with your overall investing strategy and what else should be considered can keep you from developing tunnel vision.

Overbought and Oversold levels

The stock has RSI reading of 49.6. RSI gives an indication of the impending reversals or reaction in price of a security. RSI moves in the range of 0 and 100. So an RSI of 0 means that the stock price has fallen in all of the 14 trading days. Similarly, an RSI of 100 means that the stock price has risen in all of the 14 trading days. In technical analysis, an RSI of above 70 is considered an overbought area while an RSI of less than 30 is considered as an oversold area. RSI can be used as a leading indicator as it normally tops and bottoms ahead of the market, thereby indicating an imminent correction in the price of a security. It is pertinent to note that the levels of 70 and 30 needs to be adjusted according to the inherent volatility of the security in question.

Analyst Watch: Analysts have assigned their consensus opinion on this stock with rating of 3.2 on scale of 1 to 5. 1 or 2 =>Buy view 4 or 5 => Sell opinion. 3 =>Hold. Analysts recommendations are the fountainhead of equity research reports and should be used in tangent with proprietary research and investment methodologies in order to make investment decisions.

See original here:
Vir Biotechnology (VIR): Stock on the Move - Investor Welcome

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton, M.D. to the Companys Board of Directors.

"Julie is an accomplished biotechnology executive who brings extensive oncology clinical drug development expertise to our Board of Directors," said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. "As we continue to advance AO-176 in clinical development for select solid tumors and plan for additional indications in hematologic malignancies including multiple myeloma, I am thrilled to have Julie join the Board of Directors. We share a deep commitment to developing novel therapies for patients with cancer and I look forward to working with her."

Julie Hambleton, M.D., Chief Medical Officer at IDEAYA Biosciences and Director for Arch Oncology, added, "I am very encouraged by the growing body of preclinical data, the clinical progress, and future clinical potential of AO-176. This novel anti-CD47 antibody has a best-in-class profile and I look forward to sharing my insights gained over 20 years in drug development to guide ongoing and future potential opportunities for AO-176 in across various oncology indications."

Julie Hambleton, M.D. is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and Special Protocol Assessments (SPAs). Dr. Hambleton serves as Chief Medical Officer of IDEAYA Biosciences. Previously, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Previously, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics and Vice President, Clinical Development, at Clovis Oncology. Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director,Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin.

Dr. Hambleton completed her medical and hematology-oncology training at the University California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

In addition, Dr. Hambleton serves as a Director on IGM Biosciences Board of Directors.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with select solid tumors and hematologic malignancies, including multiple myeloma. The Companys next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncologys lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of antibody pipeline programs for the treatment cancer. For more information please visit http://www.archoncology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005212/en/

Contacts

Amy Figueroa, CFAFor Arch Oncologyafigueroa@archoncology.com 650-823-2704

Continued here:
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors - Yahoo Finance

The Aptamers Market report offers a complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Aptamers market. The market report is sure to lend a hand in enhancing sales and improving return on investment (ROI). This market research report provides clients with the supreme level of market data and information which is specific to their niche and their business requirements. This global Aptamers market research report is a proven source to gain valuable market insights and take better decisions about the important business strategies.

Request for sample copy or PDF Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-digital-health-technologies-market

Global Aptamers Marketis expected to rise from its initial estimated value of USD 176.86 million in 2018 to an estimated value of USD 722.69 million by 2026, registering a CAGR of 19.01% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing R&D investments in biotechnology and pharmaceutical sectors.

Few of the major competitors currently working in the globalaptamers marketareAptamer Sciences, Inc., AMBiotech, Aptagen, LLC., Aptamer Group, Aptus Biotech, Base Pair Biotechnologies, Cambio, NeoVentures Biotechnology Inc., SOMALOGIC, INC., TriLink BioTechnologies, LLC, Vivonics Inc., NOXXON Pharma, 2bind GmbH, NOVAPTECH, Donovan Biotechnology, LLC, ATDBio Ltd., AuramerBio, Barrick Lab, Creative Biogene, AMS Biotechnology (Europe) Limited, IBA GmbH and Kaneka Corporation among others.

Market Definition: Global Aptamers Market

Aptamersare single-stranded DNA or RNA (ssDNA or ssRNA) molecules. Aptamers are the oligonucleotide or peptide molecules that bind to a specific target molecule. It assumes to have a variety of shapes due to their tendency to form helices and single-stranded loops. There are many advantages of these small molecules in comparison to the antibodies.

Technology market research report are based upon SWOT analysis on which businesses can rely confidently.

Segmentation: Global Aptamers Market

Aptamers Market : By Type

Aptamers Market : By Application

Aptamers Market : By Technology

Aptamers Market : By End User

Aptamers Market : ByGeography

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-aptamers-market

Key Developments in the Aptamers Market:

Aptamers Market Drivers

Aptamers Market Restraints

Aptamers Market : Competitive Analysis

Global aptamers market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global aptamers market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Features mentioned in the report

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-aptamers-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

More:
Aptamers Market Business intelligence Report and financial Insights. Top Companies are TriLink BioTechnologies, LLC, Vivonics Inc., NOXXON Pharma,...

The president of BioCubaFarma, Eduardo Martnez, highlighted in the Mesa Redonda television program that in the fight against the coronavirus, his institution has a plan that covers different aspects, one of which is to guarantee the medicines designed for the protocols. He ensured their availability for patients who could be diagnosed, even in the worst case scenario.

He said that BioCubaFarma has also joined the production of soaps, disinfectants, hydroalcoholic solutions and protection means. He added that the antiviral action of interferon has been shown to be effective in treating the disease, along with other products developed by the biopharmaceutical industry. He said that many countries had asked Cuba for support in the supply of medicines. To date, 62 nations have requested interferon.

He insisted that asymptomatic patients constitute the fundamental cause of the spread of the epidemic; hence the importance of mass screening to identify suspects and isolate them. It is an international and local challenge, he said. This April 12, more than 2,000 tests were made in Cuba to diagnose the disease.

For his part, the director of the Finlay Vaccine Institute, Dr. Vicente Vrez, reported that even though the search for a vaccine will take time, there are other options to improve patients immune systems.

Cuba, he said, today has two vaccines used to fight both cancer and allergies, and they will start being applied to risk groups. Their purpose is aimed at strengthening peoples immune system. He explained that several researchers are working on a project aimed at finding out the incidence of these vaccines in patients to prevent them from developing a serious condition.

However, he said that the most important thing was social isolation, the use of the facemask and eyeglasses. All this makes it possible to put up a barrier against the virus and decrease the viral load in case of illness.

The director of the Center for Genetic Engineering and Biotechnology, Dr. Mara del Carmen Domnguez Orta, said that the institution has a research base of 20 years. A specific product, Molecule 258, is intended to regulate peoples immune systems and control inflammation of the organs without generating immunosuppression.

It has been applied, she said, in three critically ill patients at the IPK and the Naval Hospital with positive results, but, she pointed out, it is only used when there are no other options and with the prior consent of family members.

She stressed that this medicine is not a cure, but a therapeutic alternative, hence the importance of complying with prevention measures.

Lastly, Dr. Gerardo Guilln Nieto, director of Biomedical Research at the Center for Genetic Engineering and Biotechnology, said that the vaccine to strengthen innate immunity to COVID-19 is in the final phase of study.

The vaccine, which is applied sublingually, enhances immunity to the entry of the virus, he said, explaining that the samples analyzed after the application of the drug confirm that it stimulates the molecules that mark the activation of the innate immune system.

That vaccine will be favorable to the most vulnerable groups and will help them stimulate the immune response against the virus.

The rest is here:
Role of Cuban science and biotechnology against coronavirus addressed - OnCubaNews

The 72 rating InvestorsObserver gives to Iovance Biotherapeutics Inc (IOVA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, IOVAs 72 overall rating means the stock scores better than 72 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock has risen 13.99% while the S&P 500 is unchanged 0% as of 9:50 AM on Tuesday, Apr 14. IOVA is higher by $4.23 from the previous closing price of $30.23 on volume of 285,317 shares. Over the past year the S&P 500 is down -4.95% while IOVA is higher by 209.06%. IOVA lost -$1.59 per share the over the last 12 months.

To screen for more stocks like IOVA click here.

See more here:
Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? - InvestorsObserver

Global Biotechnology Reagents Market 2020-2024 The analyst has been monitoring the biotechnology reagents market and it is poised to grow by $ 37. 87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period.

New York, April 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biotechnology Reagents Market 2020-2024" - https://www.reportlinker.com/p04821786/?utm_source=GNW Our reports on biotechnology reagents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the presence of high-throughput and novel technologies and high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, the presence of high-throughput and novel technologies is anticipated to boost the growth of the market as well. The biotechnology reagents market analysis includes technology segments and geographic landscapes

The biotechnology reagents market is segmented as below: By Technology Chromatography In-vitro diagnostics Polymerase chain reaction Cell culture Others

By Geographic Landscapes APAC Europe North America ROW

This study identifies the increasing R&D investments by federal agencies and biotechnology firms as one of the prime reasons driving the biotechnology reagents market growth during the next few years. The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our biotechnology reagents market covers the following areas: Biotechnology reagents market sizing Biotechnology reagents market forecast Biotechnology reagents market industry analysis

Read the full report: https://www.reportlinker.com/p04821786/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original post here:
The Global Biotechnology Reagents Market is expected to grow by $ 37.87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period -...

Biotechnology Algae Cultivation Process (Micro Algae) Market Forecast 2020-2026

The Global Biotechnology Algae Cultivation Process (Micro Algae) 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Biotechnology Algae Cultivation Process (Micro Algae) analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

The key manufacturers covered in this report are: Cellana, LGem, Solix Biofuels, Ecoduna, Seambiotic, Algenol Biofuels, DENSO, Solazyme, Sapphire Energy, Cyanotech, Mialgae, and Neoalgae

This report also includes the overall and comprehensive study of the Biotechnology Algae Cultivation Process (Micro Algae) with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Biotechnology Algae Cultivation Process (Micro Algae) industry and provides data for making strategies to increase the market growth and effectiveness.

Development policies and plans are discussed as well as Manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

In addition to this, regional analysis is conducted to identify the leading region and calculate its share in the global Biotechnology Algae Cultivation Process (Micro Algae) . Various factors positively impacting the growth of the Biotechnology Algae Cultivation Process (Micro Algae) in the leading region are also discussed in the report. The global Biotechnology Algae Cultivation Process (Micro Algae) is also segmented on the basis of types, end users, geography and other segments.

Objective of Studies:

To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Biotechnology Algae Cultivation Process (Micro Algae) market.

To provide insights about factors affecting the market growth. To analyze the Biotechnology Algae Cultivation Process (Micro Algae) market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

To provide country level analysis of the market with respect to the current market size and future prospective.

To provide country level analysis of the market for segment by application, product type and sub-segments.

To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Biotechnology Algae Cultivation Process (Micro Algae) market.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Get Complete Report with Detailing TOC at Discounted Rate :https://www.reportsandmarkets.com/reports/global-biotechnology-algae-cultivation-process-micro-algae-market-2020-by-company-regions-type-and-application-forecast-to-2025?utm_source=jewishlifenews&utm_medium=15

Table of Content:

1 Study Coverage

2 Executive Summaries

3 Breakdown Data by Manufacturers

4 Breakdown Data by Type

5 Breakdown Data by Application

6 North America

7 Europe

8 Asia Pacific

9 Central & South America

Applications

10 Middle East and Africa

11 Company Profiles

12 Future Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

14 Value Chain and Sales Channels Analysis

15 Research Findings and Conclusion

16 Appendix

About us

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. This helps in understanding the market players and the growth forecast of the products and so the company. This is where market research companies come into the picture. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Contact Person

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Here is the original post:
Biotechnology Algae Cultivation Process (Micro Algae) Market Competitive Analysis and Top Profiling Forecasts to 2026 | Cellana, LGem, Solix Biofuels,...

The "High-performance Liquid Chromatography (HPLC) Market by Product (Instruments (Systems, Detectors), Consumables (Columns, Filters), and Accessories), Application (Clinical Research, Diagnostics, Forensics), Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The report analyzes the HPLC market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

The global HPLC market is projected to reach USD 5,679.6 million by 2025 from USD 4,540.2 million in 2020, rising at a CAGR of 4.6%.

The key factors driving the growth of this market include the high sensitivity and accuracy of the HPLC technique, the growing importance of HPLC tests in drug approvals, improving the popularity of hyphenated techniques, and increasing pharmaceutical R&D spending. However, the high cost of HPLC systems is expected to restrict market growth to a certain extent.

Adoption of HPLC Instrument is expected to increase during the forecast period.

The acceptance of HPLC instruments is expected to rise due to the growing prevalence of patented studies and clinical trials. Growth in the research & development of pharmaceutical, biotechnology, food industry, agricultural industry, cosmetics, diagnostics, and forensic sciences will drive the growth of this segment. Consumables will also show a higher growth rate during the forecast period.

The clinical research segment will grow at the highest rate during the forecast period.

An increase in drug development studies, testing for raw materials, analysis of carbon, hydrogen, nitrogen, sulfur, chlorine, and oxygen in organic compounds and determining the presence of impurities has created a demand for advanced analysis equipment. An increase in research in various countries and a growth in clinical trial studies shows growth opportunities for this market.

The market in North America is projected to witness the highest growth rate during the forecast period (2020-2025).

North America is expected to account for the largest share of the global HPLC market. Market growth in this region is driven primarily by the increase in the funding for R&D, a growing number of preclinical activities by CROs and pharmaceutical companies, and the increasing food and agricultural industry in Canada. On the other hand, Asia-Pacific is projected to have the highest growth rate in the forecast period. The high growth rate of the Asian region can be attributed to factors such as extensive sales of biosimilars and generics in Japan, and the growth in the pharma and biotech sectors in India and China are some of the major factors driving the growth of the HPLC market in this region.

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 High-Performance Liquid Chromatography Market Overview

4.2 Geographic Analysis: North American HPLC Market, by Product

4.3 HPLC Market Share, by Product, 2020 vs. 2025

4.4 HPLC Market Share, by Application, 2020 vs. 2025

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 High Sensitivity and Accuracy of the HPLC Technique

5.2.1.2 Growing Popularity of Hyphenated Techniques

5.2.1.3 Growing Importance of HPLC Tests in Drug Approvals

5.2.1.4 Increasing Pharmaceutical R&D Spending

5.2.2 Restraints

5.2.2.1 High Cost of Equipment

5.2.2.2 Dearth of Skilled Professionals

5.2.3 Opportunities

5.2.3.1 Increasing Use of Chromatography in the Purification of Monoclonal Antibodies

5.2.3.2 Emerging Markets in the Asia Pacific Region

5.2.4 Challenges

5.2.4.1 Extensive Requirements in Developing Systems that Generate Pressure Above 20,000 PSI

5.2.4.2 Lack of Long-Term Reproducibility

6 High-Performance Liquid Chromatography Market, by Product

6.1 Introduction

6.2 Instruments

6.2.1 HPLC Systems

6.2.1.1 HPLC Systems Dominated the Instruments Market in 2019

6.2.2 Pumps

6.2.2.1 Rising Demand for High-Pressure Pumps to Drive Market Growth

6.2.3 Detectors

6.2.3.1 Need for the Precise Detection of Minute Analyte Concentration to Boost Market Growth

Story continues

6.2.4 Fraction Collectors

6.2.4.1 Technological Advancements to Drive the Demand for Fraction Collectors

6.3 Consumables

6.3.1 Columns

6.3.1.1 Growth in R&D to Boost the HPLC Columns Market

6.3.1.2 Reversed-Phase HPLC Columns

6.3.1.3 Ion-Exchange HPLC Columns

6.3.1.4 Normal Phase/Hydrophilic Interaction HPLC Columns

6.3.1.5 Other HPLC Columns

6.3.2 Filters

6.3.2.1 Need for Efficient Filters is High As they Increase the Lifespan of Expensive Analytical Columns

6.3.3 Vials

6.3.3.1 Vial Selection is an Important Step in Chromatography

6.3.4 Tubes

6.3.4.1 Material Improvements in Tubes to Support Market Growth

6.4 Accessories

7 High-Performance Liquid Chromatography Market, by Application

7.1 Introduction

7.2 Clinical Research Applications

7.2.1 Growth in the Pharmaceutical and Biotechnology Industries to Support the Growth of this Application Segment

7.3 Diagnostic Applications

7.3.1 Rising Need to Determine Metabolites and Analytes to Boost Market Growth

7.4 Forensic Applications

7.4.1 US is the Largest Market for the Forensic Applications of HPLC

7.5 Other Applications

8 High-Performance Liquid Chromatography Market, by Region

8.1 Introduction

8.2 North America

8.2.1 US

8.2.1.1 US Accounted for the Largest Share of the North American Market

8.2.2 Canada

8.2.2.1 Growth in the Food and Agricultural Sectors to Support Market Growth in Canada

8.3 Europe

8.3.1 Germany

8.3.1.1 Increasing Life Science Research to Aid Market Growth in Germany

8.3.2 UK

8.3.2.1 Growth in the Biotechnology Sector to Drive Market Growth in the UK

8.3.3 France

8.3.3.1 Faster Approvals for Clinical Trials to Drive the Demand for HPLC in France

8.3.4 Italy

8.3.4.1 Growth in the Biotechnology and Pharmaceutical Industries to Support Market Growth in Italy

8.3.5 Spain

8.3.5.1 Growth in the Biotechnology Industry to Drive Market Growth in Spain

8.3.6 Rest of Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.1.1 Rising Production of Biosimilars and Generics to Support Market Growth in Japan

8.4.2 China

8.4.2.1 Growth in the Biotechnology Sector to Support Market Growth in China

8.4.3 India

8.4.3.1 Growing Pharmaceutical Sector to Support Market Growth in India

8.4.4 Rest of Asia Pacific

8.5 Rest of the World

8.5.1 Middle East and Africa

More:
$5.6 Bn High-performance Liquid Chromatography (HPLC) Market by Product, Application and Region - Forecast to 2025 - ResearchAndMarkets.com - Yahoo...

Scientists around the world are scrambling to find a vaccine the ultimate Covid-19 panacea.

There are now 70 candidate vaccines in development, up from to 44 on March 20, according to a document from WHO published Saturday. Experts expect it to take between 12 and 18 months to get a vaccine approved for mass use.

Of the 70 Covid-19 vaccines in development, only three are currently in clinical trials, meaning they are being tested on humans. Clinical trials are designed to assess the safety and efficacy of a new drug and consist of several phases, each involving more patients.

China's CanSino Biological, in partnership with the Beijing Institute of Biotechnology, is in the lead, with the only candidate vaccine currently in phase two trials. U.S. players Moderna and Inovio Pharmaceuticals are the other two developers testing vaccines on humans and both are currently in phase one. The remaining 67 potential vaccines are still only in the pre-clinical trial stage.

To bridge the gap between now and then when a vaccine is approved scientists continue to search for effective treatments, with efforts focused on several existing drugs.

British health-care giant AstraZeneca has joined this effort, announcing today that it would start a clinical trial to assess the potential of Calquence, a drug already approved for the treatment of leukaemia, in the treatment of the immune response associated with Covid-19. The trial is expected to open for enrolment in the coming days in the U.S. and several countries in Europe.

An Israeli scientist works at a laboratory at the MIGAL Research Institute in Kiryat Shmona in the upper Galilee in northern Israel on March 1, 2020 where efforts are underway to produce a vaccine against the COVID-19 coronavirus adapted from another for infectious bronchitis virus.

Jalaa Marey | AFP | Getty Images

Separately, there has been some encouraging news on Gilead's remdesivir, a drug originally developed to treat Ebola. New data published April 10 in the New England Journal of Medicine revealed that 68% of 53 hospitalized patients showed improvement after taking the drug. However, this was not a controlled study (rather, the data came from a compassionate use program which is where experimental drugs are offered to patients who have a disease with no authorized therapies), so experts urge caution when interpreting these findings.

Meanwhile, concerns are mounting around the safety of anti-malaria drugs chloroquine and hydroxychloroquine, touted by U.S. President Donald Trump as promising treatments. News emerged over the weekend that a chloroquine trial in Brazil was cut short after researchers found a high dose was associated with an irregular heartbeat.

Speaking at a coronavirus briefing in Geneva Monday, WHO Executive Director of the Health Emergencies Programme Dr. Michael Ryan commented: "The medical and research community are really taking the potential of hydroxychloroquine seriously and chloroquine seriously, and it's currently (involved) in a number of different trials."

However he added: "There is no empirical evidence, there is no evidence from randomized control trials that it works, and clinicians have also been cautioned to look out for side effects of the drug."

Read more:
There are now 70 coronavirus vaccines in development, as the race to find treatments also gathers pace - CNBC

New Jersey, United States,- The report is a must-have for business strategists, participants, consultants, researchers, investors, entrepreneurs, and other interested parties associated with the Nanoparticles in Biotechnology and Pharmaceuticals Market. It is also a highly useful resource for those looking to foray into the Nanoparticles in Biotechnology and Pharmaceuticals market. Besides Porters Five Forces and SWOT analysis, it offers detailed value chain assessment, comprehensive study on market dynamics including drivers, restraints, and opportunities, recent trends, and industry performance analysis. Furthermore, it digs deep into critical aspects of key subjects such as market competition, regional growth, and market segmentation so that readers could gain sound understanding of the Nanoparticles in Biotechnology and Pharmaceuticals market.

The research study is a brilliant account of macroeconomic and microeconomic factors influencing the growth of the Nanoparticles in Biotechnology and Pharmaceuticals market. This will help market players to make appropriate changes in their approach toward attaining growth and sustaining their position in the industry. The Nanoparticles in Biotechnology and Pharmaceuticals market is segmented as per type of product, application, and geography. Each segment is evaluated in great detail so that players can focus on high-growth areas of the Nanoparticles in Biotechnology and Pharmaceuticals market and increase their sales growth. Even the competitive landscape is shed light upon for players to build powerful strategies and give a tough competition to other participants in the Nanoparticles in Biotechnology and Pharmaceuticals market.

The competitive analysis included in the report helps readers to become aware of unique characteristics of the vendor landscape and crucial factors impacting the market competition. It is a very important tool that players need to have in their arsenal for cementing a position of strength in the Nanoparticles in Biotechnology and Pharmaceuticals market. Using this report, players can use effective business tactics to attract customers and improve their growth in the Nanoparticles in Biotechnology and Pharmaceuticals market. The study provides significant details about the competitive landscape and allows players to prepare for future challenges beforehand.

Nanoparticles in Biotechnology and Pharmaceuticals Market Segmentation

This market has been divided into types, applications and regions. The growth of each segment provides a precise calculation and forecast of sales by type and application, in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting qualified niche markets. . Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, Asia-Pacific, the Middle East and Africa and Latin America. Research analysts understand competitive forces and provide competitive analysis for each competitor separately.

Nanoparticles in Biotechnology and Pharmaceuticals Market by Type:

YYYY

Nanoparticles in Biotechnology and Pharmaceuticals Market by Application:

ZZZZ

Nanoparticles in Biotechnology and Pharmaceuticals Market by Region:

North America (The USA, Canada, and Mexico)Europe (Germany, France, the UK, and Rest of Europe)Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Latin America (Brazil and Rest of Latin America.)Middle East &Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

The report answers important questions that companies may have when operating in the Nanoparticles in Biotechnology and Pharmaceuticals market. Some of the questions are given below:

What will be the size of the Nanoparticles in Biotechnology and Pharmaceuticals market in 2026?

What is the current CAGR of the Nanoparticles in Biotechnology and Pharmaceuticals market?

What products have the highest growth rates?

Which application is projected to gain a lions share of the Nanoparticles in Biotechnology and Pharmaceuticals market?

Which region is foretold to create the most number of opportunities in the Nanoparticles in Biotechnology and Pharmaceuticals market?

Which are the top players currently operating in the Nanoparticles in Biotechnology and Pharmaceuticals market?

How will the market situation change over the next few years?

What are the common business tactics adopted by players?

What is the growth outlook of the Nanoparticles in Biotechnology and Pharmaceuticals market?

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=001

Reasons to Buy the Report

Upgrade your market research resources with this comprehensive and accurate report on the Nanoparticles in Biotechnology and Pharmaceuticals market

Get complete understanding of general market scenarios and future market situations to prepare for rising above the challenges and ensuring strong growth

The report offers in-depth research and various tendencies of the Nanoparticles in Biotechnology and Pharmaceuticals market

It provides detailed analysis of changing market trends, current and future technologies used, and various strategies adopted by leading players of the Nanoparticles in Biotechnology and Pharmaceuticals market

It offers recommendations and advice for new entrants of the Nanoparticles in Biotechnology and Pharmaceuticals market and carefully guides established players for further market growth

Apart from hottest technological advances in the Nanoparticles in Biotechnology and Pharmaceuticals market, it brings to light the future plans of dominant players in the industry

Table of Contents

Market Overview: This section comes under executive summary and is divided into four sub-sections. It basically introduces the Nanoparticles in Biotechnology and Pharmaceuticals market while focusing on market size by revenue and production, market segments by type, application, and region, and product scope.

Competition by Manufacturers: It includes five sub-sections, viz. market competitive situation and trends, manufacturers products, areas served, and production sites, average price by manufacturers, revenue share by manufacturers, and production share by manufacturers.

Market Share by Region: It provides regional market shares by production and revenue besides giving details about gross margin, price, and other factors related to the growth of regional markets studied in the report. The review period considered here is 2015-2019.

Company Profiles: Each player is assessed for its market growth in terms of different factors such as markets served, gross margin, price, revenue, production, product specification, and areas served.

Manufacturing Cost Analysis: It is sub-divided into four chapters, viz. industrial chain analysis, manufacturing process analysis, manufacturing cost structure, and key raw materials analysis.

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Nanomagnetic Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Naphthalene Water Reducers Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more here:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Key Players, Share, Trend, Segmentation and Forecast to 2026 - Cole of Duty

The global market formedia, sera and reagents in biotechnologyshould reach $5.5 billion by 2023 from $4.1 billion in 2018 at a compound annual growth rate (CAGR) of 6.0% for the period 2018-2023.

Report Scope:

Cell culture products are used from the point of drug discovery through the process of drug development. Cell culture products are used mainly for research purposes, for production of biopharmaceuticals, and for educational purposes. This report focuses on the global market for media, sera and reagent products used in the cell culture industry and discusses the applications in various arenas of biomedical and life science research. The report addresses the whole market for cell culture including the research segment, production segment, contract segment, and others segment, which includes the in vitro diagnostics and educational sector.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/12029

The scope of the study is worldwide. Current market dynamics, market drivers, restraints, trends, regulatory issues, and strategic developments are discussed in the report. In the regional analysis, the report identifies and analyzes market size and forecasts for the U.S., Europe and emerging markets. The emerging markets for media, sera and reagents in biotechnology include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, and other countries.

Also included in the report are relevant patent analyses and comprehensive profiles of companies that lead the market for media, sera and reagents in the cell culture industry. A few prominent players in this industry are Thermo Fisher Scientific, Merck KGaA, GE Healthcare Life Sciences, BD Biosciences, and Corning Inc.

Report Includes:

An overview of the global markets and technologies for media, sera and reagents used in biotechnology. Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. Information on different types of cell cultures and products from cell culture technology as well as the advantages and disadvantages for the use of various types of media. Detailed analysis of the cell culture industrys structure. Discussion covering the applications of cell culture technology with an emphasis on usage in the research, production, and contract segments. Profiles of major players in the media, sera, and reagents industry.

Report Summary

In the past decade, there has been a significant shift in the nature of the products being manufactured and sold by biotechnology companies. Innovative products are coming to market that help to increase the growth and differentiation of cells in in vitro conditions. Launch of innovative cell culture products and growing demand for biopharmaceuticals reflect increased use of cell culture products.

The global biopharmaceutical portfolio of today is a sign of increased therapeutic competition and expansion in a number of targeted therapies. These trends have given rise to highly specific manufacturing requirements, including cell culture media, sera and reagents. The fundamental shift in the pharmaceutical industry from small-molecule or chemical-based drugs towards biotherapeutics and a focus on consistently improving the efficiency and effectiveness of production are spurring an evolution in cell culture technology that is needed to support advanced biopharmaceutical manufacturing. Development of cell culture products, especially serum-free and animal-component-free media, has improved manufacturing processes by conferring many advantages.

The global market for cell culture products is driven by increased demand for biologics including biosimilars; by use of cell-based methods for vaccine production; and by use of cell lines for new drug developments. Ever-increasing demand for biopharmaceuticals has forced manufacturers to move toward contract manufacturing and research organizations, which will help the cell culture market to grow further during the forecast period of 2016 to 2021.

This report analyzes the market under three main segments: sera, media and reagents. All three categories are witnessing growth because of increased demand for biopharmaceuticals and research activities in the field of regenerative medicine. Use of mammalian cells to increase capacity, scalability and flexibility in vaccine production is an additional factor for the growth of the cell culture product market. Major companies operating in the cell culture market include BD Biosciences, Lonza Group, Sigma-Aldrich Corp. (a part of Merck KGaA), and Thermo Fisher Scientific Inc.

Innovation in biotechnology is interrelated with research and development (R&D) discoveries. As the biopharmaceutical portfolio continues to evolve, the manufacturing technologies and superior cell culture products offered by companies such as Sartorius Stedim Biotech SA, EMD Millipore (a part of Merck KGaA), and others will continue to advance in the coming years.

In 2015, the U.S. was the largest market for cell culture products, accounting for about 42.1% of the global market. The U.S. has one of the most supportive environments for the development and commercialization of new drugs, as it is the worlds largest free-pricing market for pharmaceuticals and has high per capita incomes. A large elderly population and high rates of chronic diseases and affordability are other factors that make the U.S. suitable for the development and consumption of drugs. Support from the government for medical research, an unparalleled scientific and research base, and an innovative biotechnology sector are the major factors that make the U.S. market the preferred home for growth in the healthcare industry, which also includes biotechnology.

More Info of Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/12029

Continue reading here:
Media, Sera And Reagents In Biotechnology Market Insights on Trends, Application, Types and Users Analysis COVID-19 2023 - 3rd Watch News

AbbVie is partnering with Genmab A/Sto commercialise up to seven new antibody formats.

Under the licence agreement, AbbVie will pay Genmab US$750m upfront and up to US$3.15bn in potential milestones. In addition to co-developing three of Genmabs early-stage investigational bispecific DuoBody antibody product candidates (epcoritamab, DuoBody-CD3xCD20; DuoHexaBody-CD37 and DuoBody-CD3x5T4), the companies agreed to enter into a discovery research collaboration for developing future antibody therapeutics against cancer.

Under the discovery research collaboration, the new partners will combine Genmabs DuoBody technology and AbbVies ADC technology to develop up to four additional antibody conjugates, potentially across both solid tumours and blood cancers. Genmabs DuoBody-CD3 technology engages and directs cytotoxic T cells to selectively activate an immune response towards malignant cells. AbbVies ADC technology allows the selective delivery of a highly toxic compound directly to cancer cells that overexpress specific surface markers. The companies said this combined strategy may allow designing effective cancer therapies with fewer side effects.

For epcoritamab, companies will share commercial responsibilities in the U.S. and Japan, with AbbVie being responsible for the global commercialisation. Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales. For DuoHexaBody-CD37, DuoBody-CD3x5T4 and any product candidates resulting from the companies discovery research collaboration, Genmab and AbbVie will share responsibilities for global development and commercialization in the U.S. and Japan. Genmab retains the right to co-commercialize these products, along with AbbVie, outside of the U.S. and Japan. For the discovery research partnership, Genmab will conduct Phase 1 studies for these programmes. AbbVie retains the right to opt-in for programme development

Upon market approval of Genmabs product candidates, Abbvie will pay tiered royalties between 22% and 26% on net sales for epcoritamab outside the U.S. and Japan. Except for these royalty-bearing sales, the parties share in pre-tax profits from the sale of products on a 50-50 basis. These potential milestones are up to US$1.15bn in payments related to clinical development and commercial success across the three existing bispecific antibody programmes. Furthermore, if all four next-generation antibody product candidates developed as a result of the discovery research collaboration are successful, Genmab is eligible to receive up to US$2bn in option exercise and success-based milestone payments.

See original here:
Abbvie and Genmab team up in oncology - European Biotechnology News

Cara Therapeutics Inc (CARA) is near the middle in its industry group according to InvestorsObserver. CARA gets an overall rating of 62. That means it scores higher than 62 percent of stocks. Cara Therapeutics Inc gets a 53 rank in the Biotechnology industry. Biotechnology is number 8 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Cara Therapeutics Inc (CARA) stock is lower by -1.23% while the S&P 500 has gained 0.62% as of 2:19 PM on Wednesday, May 27. CARA has fallen -$0.20 from the previous closing price of $16.31 on volume of 372,663 shares. Over the past year the S&P 500 is higher by 7.42% while CARA has fallen -10.40%. CARA lost -$2.55 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Cara Therapeutics Inc click here.

See more here:
Where Does Cara Therapeutics Inc (CARA) Stock Fall in the Biotechnology Field? - InvestorsObserver

FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that the first patient has been dosed in the National Cancer Institutes (NCI) Phase 2 clinical study of PDS0101 in the treatment of advanced human papillomavirus (HPV) associated cancers. This clinical trial involves a combination of PDS0101 with two clinical development-stage immune-modulating agents, Bintrafusp alfa (M7824) and NHS-IL12.

The NCI Center for Cancer Researchs Genitourinary Malignancies Branch (GMB) and Laboratory of Tumor Immunology and Biology (LTIB) are jointly leading this Phase 2 trial evaluating PDS0101, which combines the Versamune platform with targeted antigens in HPV-expressing cancers, in combination with Bintrafusp alfa (M7824) and NHS-IL12.

The trial will evaluate the objective response rate of this novel triple combination in approximately 35 patients with advanced HPV-associated cancers. The first eight patients will be evaluated for safety and objective response before the trial progresses to full enrollment.

We are excited to have the first patient dosed in this NCI-led Phase 2 clinical trial, which is an important next step in further demonstrating the power of our novel Versamune platform to induce high levels of tumor-specific CD8 killer T-cells, commented Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. We believe that PDS0101s demonstrated preclinical efficacy when combined with these two immune-modulating agents, has the potential to significantly improve clinical outcomes for patients with advanced HPV-associated cancers.

Dr. Jeffrey Schlom, Chief, LTIB, and Dr. James Gulley, Chief, GMB, at NCI are serving as principal investigators for the NCI, while Dr. Frank Bedu-Addo and Dr. Lauren Wood, PDS Biotechs Chief Executive Officer and Chief Medical Officer respectively, will serve as PDS Biotechs investigators. The studies are being performed as part of a Cooperative Research and Development Agreement (CRADA) between PDS Biotech and the NCI.

Dr. Julius Strauss, Staff Clinician, LTIB, is serving as the principal investigator of this phase 2 clinical trial of PDS0101 in advanced HPV-associated cancers. For patients interested in enrolling in this clinical study, please call NCIs toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email NCIMO_Referrals@mail.nih.gov, and/or visit the website:https://trials.cancer.gov.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck & Co., PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with standard of care chemoradiotherapy.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

See the original post:
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute - GlobeNewswire

A rating of 9 puts Therapix Biosciences Ltd - ADR (TRPX) near the bottom of the Biotechnology industry according to InvestorsObserver. Therapix Biosciences Ltd - ADR's score of 9 means it scores higher than 9% of stocks in the industry. Therapix Biosciences Ltd - ADR also received an overall rating of 22, putting it above 22% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 22 would rank higher than 22 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Therapix Biosciences Ltd - ADR (TRPX) stock is down -2.31% while the S&P 500 is up 0.05% as of 11:03 AM on Tuesday, May 19. TRPX is lower by -$0.01 from the previous closing price of $0.42 on volume of 654,488 shares. Over the past year the S&P 500 has gained 4.05% while TRPX is lower by -87.27%. TRPX lost -$2.40 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more here:
Where Does Therapix Biosciences Ltd - ADR (TRPX) Stock Fall in the Biotechnology Field? - InvestorsObserver

Digital Cell-Sorting System Market Research Report How Effective in Covid-19 with latest technology, growth rate, prices, market size, trading, and key vendors of the industrys information with forecast from 2020 to 2027. This research report also combines industry-wide statistically relevant quantitative data and relevant and insightful qualitative analysis. This report has published stating that the global Digital Cell-Sorting System Market is anticipated to expand significantly at Million US$ in 2020 and is projected to reach Million US$ by 2027, at a CAGR of during the forecast period.

A complete study of the competitive landscape of the global Digital Cell-Sorting System Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This study also provides an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Request Sample Copy of this Report @: https://www.healthcareintelligencemarkets.com/request_sample.php?id=68724

Some of the key players operated in this report are:

Key questions answered in this report:

Factors that drive global opportunities have been surveyed in this research report to understand the current and prospective growth of the businesses. This study also offers an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Get Up To 40% Discount on this Premium Report @: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=68724

Regional Analysis:

Finally, all aspects of the global Digital Cell-Sorting System Market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

Major TOC points:

For More Information: https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=68724

*If you need anything more than these then let us know and we will prepare the report according to your requirement.

About Us:

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact Us:

Marvella Lit

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: [emailprotected]

Web: http://www.healthcareintelligencemarkets.com

Phone: +44-753-712-1342

See the original post:
Digital Cell-Sorting System Market Is Set for a Rapid Growth and is Expected to Reach USD Billion by 2027 | Top Vendors: Bio-Rad Laboratories, Beckman...